GLP1R and stroke disorder: Despite these essential differences, the overall message to the neuro and diabetic communities has been that: (1) the efficacy of GLP-1R agonists in animal models of stroke has been confirmed in some clinical studies using GLP-1R agonists (2) the efficacy from DPP4i shown in animal studies has been compared with the failure of the large clinical studies to show benefit in stroke prevention.